Optimizing Breast Cancer Management. - Northwestern University Feinberg School of Medicine Chicago, IL USA | Springer International Publishing AG | 2018. - 190 Pages Includes References - Cancer Treatment and Research Volume 173 .

This book presents expert opinions on a variety of key topics related to the management of breast cancer, with a focus on the implications of recent advances and research findings for clinical practice. It also explores the controversy regarding mammography screening and reviews the contribution of new imaging modalities. Considerable attention is paid to developments in surgical procedures, including the potential for the safe and effective use of sentinel lymph node dissection alone—even in patients with positive nodes—and to the advantages and contraindications of new radiotherapy techniques. Genetic aspects are discussed in detail, including an assessment of the role of genetic testing and the potential impact of genetic signatures on breast cancer management. New systemic strategies, such as anti-HER2 therapy, endocrine agents, and agents to reverse endocrine resistance, are considered, and the optimal use of chemotherapy for early-stage and advanced-stage disease is addressed. In closing, the book shares important new insights into lifestyle risk factors, risk reduction strategies, and survivor issues, including sexual dysfunction and fertility maintenance.

ISBN: 978-3-319-70195-0 978-3-319-70197-4 (eBook)

ISSN: 0927-3042 2509-8497 (electronic) = advanced breast cancer ALND analysis anastrozole APBI aromatase inhibitor axillary dissection benefit BRCA1 BRCA2 breast cancer breast cancer patients Breast Cancer Res breast-conserving surgery cancer risk carcinoma in situ cells chemotherapy Clin Oncol cohort compared cryopreservation DCIS diagnosis dose ductal carcinoma early breast cancer early-stage breast cancer endocrine therapy Engl evaluated exemestane fertility preservation first-line follow-up fulvestrant gene Genet guidelines hormone HR-positive breast cancer improved increased Lancet letrozole locoregional long-term low-risk lubricants lumpectomy mammography mastectomy median menopausal metastatic metastatic breast cancer metastatic disease mutation carriers NCCN Oncology oocyte outcomes ovarian suppression overall survival partial breast irradiation pathogenic pembrolizumab phase postmenopausal women predictive primary tumor prognostic radiation therapy radiotherapy randomised randomized trial receptor-positive recommendations recurrence resection screening sentinel lymph node sentinel node sexual significant SLNB stage IV breast surgical syndrome systemic therapy tamoxifen techniques tissue toxicity treated vaginal variant versus WBRT whole breast radiation

LCCN: 2017957660

Subjects--Personal Names: --Gynecology, Medical / Clinical Medicine, Medical / Gynecology & Obstetrics, Medical / Oncology / General, Medical / Radiology, Radiotherapy & Nuclear Medicine, Oncology, Radiology, Breast -- Cancer -- Treatment, Medicine, Radiotherapy.